BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

Patent Plaques

WO9819679A1: CYCLOPENTYLXANTHINE DERIVATIVES FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS

Country: **WO** World Intellectual Property Organization (WIPO)

Kind: **A1** Publ.OF the Int.Appl. with Int.Search Report

Inventor(s): **McPHERSON, Margaret, Ann** , Wenvoe, Craig-y-Eos Road, Ogmore-by-Sea, Mid Glamorgan CF32 0PG, United Kingdom
DORMER, Robert, Leslie , Wenvoe, Craig-y-Eos Road, Ogmore-by-Sea, Mid Glamorgan CF32 0PG, United Kingdom
PEREIRA, Malcolm, Martin, Claude , 6 Longspears Avenue, Heath, Cardiff CF4 3NU, United Kingdom

Applicant(s): **UNIVERSITY OF WALES COLLEGE OF MEDICINE**, Heath Park, Cardiff CF4 4XN, United Kingdom
News, Profiles, Stocks and More about this company

Issued/Filed Dates: **May 14, 1998** / Nov. 5, 1997

Application Number: **WO1997GB0003036**

IPC Class: **A61K 31/52;**

ECLA Code: **A61K31/52L5; C07D473/06;**

Priority Number(s): Nov. 5, 1996 **GB1996000229810**

Legal Status: New! Show legal status actions

Designated Countries: AU, CA, US

Abstract: The use of derivatives of theophylline for the preparation of

medicaments suitable for the treatment of Cystic Fibrosis is described. In particular, the use of 8-cyclopentyl theophylline (CPT) is described for the preparation of medicaments for the treatment of cystic fibrosis. Such medicaments may be administered orally or directly to the lung, for example, in the form of an aerosol.
[Show "fr" Abstract]

Attorney, Agent, or Firm: **NEWELL, William, Joseph;**

Family: New! Show 7 known family members

Other Abstract Info: CHEMABS 129(02)019682C CAN129(02)019682C DERABS C98-286578 DERC98-286578

Foreign References: (No patents reference this one)

administration.

4. The use according to Claim 6 wherein the medica
administered in an amount of 0.001 to 25 mg/kg body
per day.

5. The use according to Claim 1 or Claim 2 wher
medicament is suitable for administering directly
lung.

6. The use according to Claim 5 wherein the medica
a pharmaceutically acceptable aerosol.

17

Claims

1. The use of a compound of formula (1),



wherein R^1 and R^2 are the same or different a
represents an alkyl group having from 1 to 5 carbo
provided that R^1 and R^2 are not both propyl groups,
preparation of a medicament for the treatment of
fibrosis.

2. The use according to Claim 1 of a compound of
(1) wherein R^1 and R^2 are both methyl groups.

3. The use according to Claim 1 or Claim 2 wher
medicament is suitable for oral or pa



wherein R^1 and R^2 are the same or different a
represents an alkyl group having from 1 to 5 carbo

7. The use according to Claim 6 wherein the contains from 0.001 to 0.01% w/w of the compound of (1).

8. A compound of formula (1)



wherein R^1 and R^2 are the same or different a represents an alkyl group having from 1 to 5 carbo provided R^1 and R^2 are not both methyl groups or groups.

9. A pharmaceutical formulation comprising a com formula (1)

provided R^1 and R^2 are not both propyl groups, togeth a pharmaceutically acceptable carrier therefor.

10. The formulation according to Claim 9 which is for oral administration.

11. The formulation according to Claim 9 which is for administration direct to the lung.

12. The formulation according to Claim 11 which i form of a pharmaceutically acceptable aerosol.

13. The formulation according to Claim 9 which is for parenteral administration.

14. A method of treating cystic fibrosis co administering a compound of formula (1)



where R^1 and R^2 are the same or different and each re an alkyl group having from 1 to 5 carbon atoms provi

R^1 and R^2 are the same or different and each repre

R^1 and R^2 are the same or different and each repre
alkyl group having from 1 to 5 carbon atoms provided
and R^2 are not both propyl groups.

15. The method of claim 14 wherein the compound of (1) is administered orally.

16. The method of claim 14 wherein the compound of (1) is administered intranasally.

17. The method of claim 14 wherein the compound of (1) is administered parenterally.